EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1419-1427

  Xuqing, Wang ^a   Lei, Cui ^a   Zhengfa, Mao ^a   Shengchun, Dang ^a   Xin, Fan ^a   Jianguo, Qu ^a   Jianxin, Zhang ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

EphB4; Papillary thyroid carcinoma; actin mRNA

Indexed keywords

EPHRIN RECEPTOR B4; FOCAL ADHESION KINASE; PAXILLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID PAPILLARY CARCINOMA; UPREGULATION;

EID: 84868142793     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0392-5     Document Type: Article

References (26)

1. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 [see comments] (translated from English). Cancer. 1998;83(12):2638-48.
2. Liu S, Semenciw R, Ugnat AM, et al. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer. 2001;85(9):1335-9.
3. Asmis LM, Gerber H, Kaempf J, et al. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J Endocrinol. 1995;145(3):513-20.
4. Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Investig. 2001;24(7):536-45.
5. Prante O, et al. Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med. 2009;50(8):1364-70.
6. Christine J, et al. BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148(6):1139-46.
7. McIver B, Grebe SK, Eberhardt NL. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metab Disord. 2004;4(3):221-34.
8. Anna G, et al. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J. 2011;58(1):31-8.
9. Wybieralska E, et al. Role of ephrins in regulation of tumor cell migration. Postepy Biochem. 2009;55:153-62.
10. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002;3:475-86.
11. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006;169:279-93.
12. Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623-32.
13. Nakada M, Drake KL, Nakada S, et al. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res. 2006;66:8492-500.
14. Vogt T, Stolz W, Welsh J, et al. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res. 1998;4:791-7.
15. Brantley-Sieders DM, Zhuang G, Hicks D, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008;118:64-78.
16. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007;67:3994-7.
17. Batlle E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. Nature. 2005;435:1126-30.
18. Cortina C, Palomo-Ponce S, Iglesias M, et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet. 2007;39:1376-83.
19. Noren NK, Lu M, Freeman AL, et al. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA. 2004;101:5583-8.
20. Yang NY, Pasquale EB, Owen LB, et al. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through rho-mediated actin cytoskeleton reorganization. J Biol Chem. 2006;281:32574-86.
21. Noren NK, Foos G, Hauser CA, et al. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006;8:815-25.
22. Liu LY, Han YC, Wu SH, et al. Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer (translated from English). World J Gastroenterol. 2008;14(13):2110-4 (in English).
23. Clevers H, Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res. 2006;66:2-5.
24. Andres AC, Ziemiecki A. Eph and ephrin signaling in mammary gland morphogenesis and cancer. J Mammary Gland Biol Neoplasia. 2003;8:475-85.
25. Kumar SR, Masood R, Spannuth WA. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer. 2007;96:1083-91.
26. Yang N-Y, Pasquale EB, Owen LB, Ethell IM. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through rho-mediated actin cytoskeleton reorganization. J Biol Chem. 2006;43:32574-86.